ClinicalTrials.gg
RecruitingNCT06826859DASHUpdated Jul 17, 2025

Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)

A Phase 1/2 interventional study of Daily aspirin (ASA) and Split dose aspirin (ASA) in Preterm Birth and Preeclampsia, sponsored by Thomas Jefferson University. Recruiting at 1 site in United States. Open to female participants aged 16 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Thomas Jefferson University · Phase 1/2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
16 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 742 studies in Premature Birth with a site in United States — 103 open to participants now, 136 under way, 9 of them phase 3. Premature Birth · United States.

Planned enrollment
84th of 529
400 · median 85
Started
2025
with 22 others
Phase 1/2
15 of 742
4 open now
Primary completion
2029-07
later than 118 of 135 live
Registered
700th of 742
by date

Among the 742 studies in Premature Birth with a site in United States, this one is the 84th largest by planned enrollment of the 529 interventional ones that give a count, is one of 23 that started in 2025, is one of 15 in phase 1/2, reaches primary completion later than 118 of the 135 other live ones, and was the 700th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

103 of the 742 studies in Premature Birth with a site in United States are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 16 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 742 studies in Premature Birth with a site in United States, or all of them as a file.
02

Study summary

Aspirin is recommended in high risk patients to reduce the risk of preeclampsia and preterm birth, which are leading causes of both maternal and neonatal morbidity and mortality, but up to 20% will have these adverse outcomes despite therapy. Gaps in knowledge regarding pregnancy specific aspirin pharmacology and the relationship of aspirin response and pregnancy outcome, along with a lack of consensus on aspirin dosing has limited the effective use of this intervention. The investigators aim to apply principles of clinical pharmacology to determine how to optimally utilize this low cost medication to improve maternal/child health outcomes. This is a Phase I/II randomized controlled trial of high risk pregnancies recommended aspirin; participants will be randomized to take aspirin either 162mg once daily, or 81mg twice a day. Outcomes evaluated will include the difference in aspirin response between these two dosing regimens, the individual factors that impact aspirin pharmacology in pregnancy, and evaluate markers or aspirin response that may be associated with pregnancy outcome.

Read the detailed description

This is an unblinded randomized controlled Phase I/II trial comparing high risk singleton pregnancies randomized to 162mg daily (daily dose) vs 81mg q12hours (split dose). Participants will be enrolled prior to 16 weeks gestation. The primary outcome is platelet inhibition as assessed by PFA-100 epinephrine closure time, assessed 2-4 weeks after initiation and again at 28-32 weeks gestation. A subset of participants will be enrolled in a pharmacokinetic study to evaluate pharmacokinetics of aspirin in pregnancy at the two dosing intervals. Secondary outcomes include urine thromboxane at each visit, platelet associated microRNAs. Individual factors associated with aspirin pharmacokinetics and pharmacodynamics in pregnancy will be assessed. Finally, the relationship between these pharmacodynamic markers and pregnancy outcome will be evaluated.

03

Conditions studied

  • Preterm Birth
  • Preeclampsia

Keywords

  • Aspirin
  • Preeclampsia
  • Preterm birth
  • Pregnancy
  • Pharmacokinetics
  • Pharmacodynamics
  • Phase I/II
  • Randomized clinical trial
04

Who can participate

Ages eligible
16 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Singleton gestation gestational age \<16 0/7 weeks, dating confirmed with ultrasound
  • ≥1 high risk factor for preeclampsia or ≥2 moderate risk factors as per United States Preventative Services Task Force (2021)
  • Recommendation for 162mg aspirin daily in pregnancy
  • Age 16-55 years old

Exclusion criteria

Exclusion criteria

  • to aspirin
  • Current or planned use of any other anticoagulation
  • Thrombocytopenia, other known or bleeding disorder
  • Abnormally elevated baseline PFA-100 epinephrine closure time prior to aspirin initiation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    Daily aspirin

    162mg aspirin daily

    Drug: Daily aspirin (ASA)

  • Experimental
    Split dose aspirin

    81mg aspirin q12 hours

    Drug: Split dose aspirin (ASA)

Interventions

06

What researchers measure

Primary outcomes

  1. Aspirin Response PFA-100 epinephrine closure time (seconds)

    Difference in PFA-100 epinephrine closure time (seconds)

    Time frame: 2-4 weeks after aspirin initiation

Secondary outcomes

  1. Aspirin response (PFA-100 epinephrine closure time)

    Difference in PFA-100 epinephrine closure time (seconds)

    Time frame: 28-32 weeks gestation

  2. Urinary thromboxane concentration

    Difference in Urine thromboxane (AspirinWorks)

    Time frame: 2-4 weeks after aspirin initiation

  3. Urinary Thromboxane concentration

    Difference in Urinary thromboxane (AspirinWorks)

    Time frame: 28-32 weeks gestation

  4. Inadequate aspirin response

    Number of participants with PFA-100 epinephrine closure time\<150 seconds

    Time frame: 2-4 weeks after aspirin initiation

  5. Inadequate aspirin response

    Number of participants with PFA-100 epinephrine closure time\<150seconds

    Time frame: 28-32 weeks gestation

  6. Preterm birth

    Number of participants with Preterm birth\<37 weeks

    Time frame: Delivery

  7. Indicated preterm birth

    Number of participants with Preterm birth\<37 weeks due to preeclampsia or fetal growth restriction

    Time frame: delivery

  8. Spontaneous preterm birth

    Number of participants with spontaneous preterm birth \<37 weeks

    Time frame: delivery

  9. MicroRNAs

    Fold-change from baseline for concentration of circulating microRNAs

    Time frame: 2-4 weeks after aspirin initiation

  10. MicroRNAs

    Fold-change from baseline for concentration of circulating microRNAs

    Time frame: 28-32 weeks gestation

  11. Placental histopathology

    Placental pathology per Amsterdam criteria. Number of participants with maternal vascular malperfusion, intervillous thrombosis

    Time frame: Delivery

  12. Birthweight

    Infant birthweight (grams)

    Time frame: Delivery

  13. Fetal growth restriction

    Number of participants diagnosed with Fetal growth restriction

    Time frame: delivery

  14. Hypertensive disorder of pregnancy

    Number of participants diagnosed with Preeclampsia or gestational hypertension

    Time frame: delivery

  15. Gestational age at delivery

    Gestational age at delivery (weeks)

    Time frame: Delivery

  16. Pregnancy loss<20 weeks

    Number of participants with Pregnancy loss (delivery, demise, miscarriage)\<20 weeks gestation

    Time frame: delivery

  17. Fetal demise

    Number of participants with Fetal demise diagnosed \>=20 weeks gestation

    Time frame: delivery

  18. Antepartum bleeding

    Number of participants with any admission for antepartum bleeding

    Time frame: Delivery

  19. Abruption

    Number of participants with Abruption diagnosed prior to or at delivery

    Time frame: delivery

  20. Placental hematoma

    Number of participants with Placental hematoma suspected on ultrasound

    Time frame: delivery

  21. Postpartum hemorrhage

    Number of participants with Postpartum hemorrhage \>1000ml

    Time frame: Delivery

  22. Adherence

    Number of participants with Adherence\>75%

    Time frame: 2-4 weeks after aspirin

  23. Adherence

    Number of participants with Adherence\>75%

    Time frame: 28-32 weeks

  24. Neonatal intraventricular hemorrhage Grade II or higher

    Number of participants with infants found to have Neonatal IVH grade II or higher diagnosed on ultrasound post natally

    Time frame: Neonatal discharge

  25. Cordblood serum thromboxane

    cordblood serum thromboxane concentration

    Time frame: Delivery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be submitted to NICHD DASH and can be requested through NICHD DASH

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: 1 year after study completion

Access criteria: Data will be submitted to NICHD DASH and may be requested through DASH

Data sharing details ↗ · dash.nichd.nih.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jul 2029, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2025
First posted
Feb 14, 2025
StartActual
Jun 26, 2025
Primary completionEst.
Jul 1, 2029
CompletionEst.
Dec 31, 2029
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06826859
Responsible party
Sponsor
First posted
Feb 14, 2025
Start date
Jun 26, 2025
Primary completion
Jul 1, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jul 17, 2025

Study contacts

Rupsa C Boelig, MD
Contact
rupsa.boelig@jefferson.edu
215-955-5000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion